Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01632397 · ClinicalTrials.gov registry record · Phase 4

Pre-exposure Prophylaxis Adherence Intervention for MSM

A Phase 4 study of Medication Adherence, sponsored by Fenway Community Health.

Completed
Registry status
Phase 4
Development phase
103
Enrollment target
1
Study location

NCT01632397: Completed Phase 4 study of Medication Adherence, sponsored by Fenway Community Health.

NCT01632397 is a Phase 4 study of Medication Adherence that has completed, run by Fenway Community Health. The registered enrollment target is 103 participants, below the 1,655-participant average among 52 other Medication Adherence trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01632397, a Phase 4 study of Medication Adherence, has completed, sponsored by Fenway Community Health.

COMPLETED
Registry status
Phase 4
Development phase
103 participants
Enrollment target
1
Study location

Study Summary

Following formative work, the proposed study is an open-label, pilot, randomized, two arm trial where subjects will receive pre-exposure prophylaxis (PrEP) for 6 months and either a cognitive-behavioral based adherence intervention or health education with supportive counseling.

Primary Outcome

This is primarily a feasiblity pilot RCT. However, the primary eventual endpoint is PrEP adherence measured daily via electronic medication adherence monitoring (Wisepill™).

Conditions Studied

Interventions

  • BEHAVIORAL CBT-based counseling
  • BEHAVIORAL Health education and supportive counseling

Study Locations (1)

Massachusetts

  • The Fenway Institute - Boston

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2011-08
Est. Completion 2014-02
Phase Phase 4
Fenway Community Health

14 total trials

What the finished NCT01632397 record still lists

NCT01632397 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 1,655-participant average among 52 other Medication Adherence trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Medication Adherence appearing as the primary indexed condition, and to 2 interventions - of which CBT-based counseling is the first listed.

NCT01632397 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01632397 about?

NCT01632397 is a clinical study titled "Pre-exposure Prophylaxis Adherence Intervention for MSM". Following formative work, the proposed study is an open-label, pilot, randomized, two arm trial where subjects will receive pre-exposure prophylaxis (PrEP) for 6 months and either a cognitive-behavioral based adherence intervention or health education with supportive counseling.

What is the current status of trial NCT01632397?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2011-08. Estimated completion is 2014-02.

What conditions does trial NCT01632397 study?

This clinical trial studies the following conditions: Medication Adherence.

What interventions are being tested in trial NCT01632397?

The interventions under investigation include: CBT-based counseling (BEHAVIORAL), Health education and supportive counseling (BEHAVIORAL).

Who is sponsoring clinical trial NCT01632397?

This trial is sponsored by Fenway Community Health, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01632397 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Medication Adherence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01632397's enrollment target sits among peer trials

103 31st of 52 higher than 22 of 52 other Medication Adherence trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Medication Adherence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04690348 · 103 participants · Phase 2

    Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

  • NCT05282277 · 103 participants · Phase 4

    Examining the Effects of Estradiol on Neural and Molecular Response to Reward

  • NCT05566769 · 103 participants · NA

    Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  • NCT05834478 · 103 participants · Phase 3

    Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01632397, the US trial registry maintained by the National Library of Medicine. NCT01632397 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.